DENTSPLY SIRONA Inc (XRAY - Free Report) is one of the leading worldwide manufacturers’ dental consumables, dental laboratory products, dental specialty products and consumable medical device products. Post DENTSPLY-SIRONA merger, the business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Currently, this York, PA- based company carries a Zacks Rank #4 (Sell) but that could change following its fourth quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: DENTSPLY reported adjusted earnings of 67 cents per share, which beat the Zacks Consensus Estimate by 2 cents and was higher than earnings of 65 cents in the year-ago quarter.
Revenues: DENTSPLY’s net sales increased to $996.5 million from $671.1 million in the year-ago period. However this came below the Zacks Consensus Estimate of $1,019.0 million. Sales of the combined businesses grew 4.3% at constant currency (cc) exchange rates.
Key Stats: Dental and Healthcare Consumables sales rose 3.4% year over year at cc, while Technologies grew 5.2% in the quarter.
Major Factors: U.S. business in the fourth quarter was negatively impacted by channel inventory reduction related to a change in distribution strategy in North America. The company expects adjusted EPS for full year 2017 in the range of $2.80 to $2.90 per diluted share.
Stock Price: Shares have risen 6.88% over the past one month, while the Zacks categorized Medical - Dental Supplies sub industry has gained roughly 2.78% over the same time frame.
Check back later for our full write up on this DENTSPLY earnings report later!
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
DENTSPLY SIRONA Inc (XRAY - Free Report) is one of the leading worldwide manufacturers’ dental consumables, dental laboratory products, dental specialty products and consumable medical device products. Post DENTSPLY-SIRONA merger, the business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Currently, this York, PA- based company carries a Zacks Rank #4 (Sell) but that could change following its fourth quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: DENTSPLY reported adjusted earnings of 67 cents per share, which beat the Zacks Consensus Estimate by 2 cents and was higher than earnings of 65 cents in the year-ago quarter.
Revenues: DENTSPLY’s net sales increased to $996.5 million from $671.1 million in the year-ago period. However this came below the Zacks Consensus Estimate of $1,019.0 million. Sales of the combined businesses grew 4.3% at constant currency (cc) exchange rates.
Key Stats: Dental and Healthcare Consumables sales rose 3.4% year over year at cc, while Technologies grew 5.2% in the quarter.
Major Factors: U.S. business in the fourth quarter was negatively impacted by channel inventory reduction related to a change in distribution strategy in North America. The company expects adjusted EPS for full year 2017 in the range of $2.80 to $2.90 per diluted share.
Stock Price: Shares have risen 6.88% over the past one month, while the Zacks categorized Medical - Dental Supplies sub industry has gained roughly 2.78% over the same time frame.
Check back later for our full write up on this DENTSPLY earnings report later!
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on XRAY - FREE